PMV PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
PMV PHARMACEUTICALS, INC. (PMVP) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 0 shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-03-06
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-12-31 was 0.00 shares.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2024-12-31 was 0.00 shares.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2024-09-30 was 0.00 shares.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2024-06-30 was 0.00 shares.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 952.66K shares.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 374.90K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | 0.00 shares 10-K · filed 2026-03-06 | ||
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-11-12 | |||
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-03 | 0.00 shares derived: sum of 3 quarters · filed 2025-03-03 | 952.66K shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 0.00 shares derived: sum of 2 quarters · filed 2024-11-07 | 952.66K shares 10-Q · filed 2024-11-07 | 952.66K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 952.66K shares 10-Q · filed 2024-08-08 | 952.66K shares derived: sum of 3 quarters · filed 2024-08-08 | 952.66K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 952.66K shares 10-Q · filed 2024-05-09 | 952.66K shares derived: sum of 2 quarters · filed 2024-05-09 | 952.66K shares derived: sum of 3 quarters · filed 2024-05-09 | 952.66K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 0.00 shares derived: sum of 2 quarters · filed 2024-02-29 | 0.00 shares derived: sum of 3 quarters · filed 2024-02-29 | 0.00 shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-09 | 0.00 shares 10-Q · filed 2023-11-09 | 0.00 shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 0.00 shares 10-Q · filed 2023-08-09 | 0.00 shares derived: sum of 3 quarters · filed 2023-08-09 | |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-10 | 0.00 shares derived: sum of 2 quarters · filed 2023-05-10 | ||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | 374.90K shares 10-K · filed 2023-03-01 | ||
| 2022-09-30 | 374.90K shares 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |